AI and computational small molecule drug discovery approaches are helping to realise the potential of targeted protein degradation (TPD) in molecular glue development.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a company that’s specialises in next-gen TPD and which is progressing a pipeline of degrader therapeutics within oncology and inflammation.

Cross discusses TPD market growth, PhoreMost’s high-throughput GlueSEEKER platform, and the future horizon of TPD, of molecular glues going forward.

You can listen to episode 230 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.